Consensus Arcutis Biotherapeutics, Inc.

Stocks

ARQT

US03969K1088

Pharmaceuticals

Real-time Estimate Cboe BZX 09:47:36 2026-10-27 EDT			5-day change	1st Jan Change
31.78 ^USD	-0.09%		-4.31%	+8.14%

10-09	Arcutis Biotherapeutics, Inc. Presents Data Across Its ZORYVE Portfolio at EADV and Fall Clinical Dermatology Conference	CI
10-09	Arcutis Biotherapeutics' Zoryve Shows Rapid Disease Clearance in Infant Atopic Dermatitis Trial	MT

Evolution of the Average Target: Arcutis Biotherapeutics, Inc.

Evolution of the Target Price: Arcutis Biotherapeutics, Inc.

Changes in Analyst Recommendations: Arcutis Biotherapeutics, Inc.

609e965b2b9a94faca7c952.dv9GUQkGhr85Xv2Aj4UI7zpWNuTrTudsTCYME_8JiRU.Gb0gIlMwzo5qHJ_64dBrplcZQdyBG5MmK3luWq9563kyzQQOXSvijnU0xQ~edcaa1eb4aaa702cd8ef39c3897e875b

Analysts' recommendations: Arcutis Biotherapeutics, Inc.

11-04	Arcutis Biotherapeutics, Inc. Announces Publication of Positive Long-Term Safety and Efficacy Data of Zoryve®? (Roflumilast) Foam 0.3% in American Journal of Clinical Dermatology	CI
25-10-29	Morgan Stanley Raises Price Target on Arcutis Biotherapeutics to $32 From $21, Keeps Overweight Rating	MT
25-10-24	Arcutis to Present New Quality of Life and Long-Term Data with Zoryve®? (Roflumilast) Cream 0.15% and 0.05% for the Treatment of Atopic Dermatology Conference	CI
24-12-30	HC Wainwright Initiates Arcutis Biotherapeutics at Buy With $19 Price Target	MT
24-08-28	Jefferies Initiates Arcutis Biotherapeutics at Buy	MT
24-05-15	Needham Adjusts Price Target on Arcutis Biotherapeutics to $18 From $16, Maintains Buy Rating	MT
24-05-15	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $18 From $17, Maintains Buy Rating	MT
24-02-28	Mizuho Securities Raises Price Target on Arcutis Biotherapeutics to $17 From $16, Maintains Buy Rating	MT
24-02-28	Needham Raises Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	MT
24-02-23	Mizuho Increases Price Target on Arcutis Biotherapeutics to $16 From $8, Maintains Buy Rating	MT
24-01-03	Mizuho Upgrades Arcutis Biotherapeutics to Buy From Neutral, Raises Price Target to $8 From $4	MT
23-11-13	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $10 From $45, Maintains Overweight Rating	MT
23-11-08	JonesTrading Downgrades Arcutis Biotherapeutics to Hold From Buy	MT
23-11-06	Needham Adjusts Price Target on Arcutis Biotherapeutics to $8 From $22, Maintains Buy Rating	MT
23-10-27	Mizuho Downgrades Arcutis Biotherapeutics to Neutral From Buy	MT
23-10-13	Goldman Sachs Downgrades Arcutis Biotherapeutics to Neutral From Buy, Adjusts Price Target to $6 From $32	MT
23-05-26	Truist Securities Lowers Price Target on Arcutis Biotherapeutics to $40 From $45, Maintains Buy Rating	MT
23-05-11	Goldman Sachs Adjusts Price Target on Arcutis Biotherapeutics to $33 From $44, Maintains Buy Rating	MT
23-05-10	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $45 From $47, Maintains Overweight Rating	MT
23-05-10	Mizuho Securities Adjusts Arcutis Biotherapeutics Price Target to $57 From $61, Maintains Buy Rating	MT
23-04-12	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $47 From $50, Keeps Overweight Rating	MT
23-03-28	Truist Securities Lowers Arcutis Biotherapeutics' Price Target to $45 From $50, Maintains Buy Rating	MT
23-03-16	Needham Adjusts Price Target on Arcutis Biotherapeutics to $24 From $46, Maintains Buy Rating	MT
23-03-01	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $50 From $51, Maintains Overweight Rating	MT
22-12-13	Morgan Stanley Adjusts Price Target on Arcutis Biotherapeutics to $51 From $49, Maintains Overweight Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	ARCUTIS BIOTHERAPEUTICS, INC.					+23%
	ELI LILLY AND COMPANY					+4.27%
	JOHNSON & JOHNSON					+4.92%
	ABBVIE INC.					-0.68%
	ROCHE HOLDING AG					-2.56%
	MERCK & CO., INC.					+13.62%
	NOVARTIS AG					-2.85%
	ASTRAZENECA PLC					+22.47%
	AMGEN INC.					-10.64%
	GILEAD SCIENCES, INC.					+0.95%
	Average					+5.25%
	Weighted average by Cap.					+3.56%